About the Study

Solid Tumors: A study of CBL0137 for relapsed or refractory solid tumors

This study is for: • Part B: - Patients who are between the ages of 1 and 21 years old - Who have been diagnosed with progressive (growing) or recurrent (has come back) diffuse intrinsic pontine glioma (DIPG) or other diffuse midline gliomas that has a mutation in the H3 K27M gene The goal of this study is to find what effects, good and/or bad, the drug CBL0137 has on children and young adults with relapsed or refractory solid tumors. Note: Children's Mercy is not participating in Part A of this study.

Interested in learning more?

Full Study Name: PEPN2111